Pharma BD Deal Intelligence

Celgene Corporation / Bristol Myers Squibb

2018 · Acquisition/Merger · $9.0B · Complete

The Street Said

Positive — critic reaction at announcement

History Says

Largely worked — most objectives met

CALLED IT — OFF BY 5

Full analysis, sources & comparables →

The coverage arc

Jan 22, 2018 Celgene 8-K/EX-99.2 - Deal Announcement Neutral

Celgene Corporation to acquire Juno Therapeutics, Inc.

Mar 06, 2018 Celgene 8-K/EX-99.2 - Completion Announcement Neutral

Celgene completes acquisition of Juno Therapeutics, Inc.

Source summaries from our enrichment pipeline; follow links for originals.

All 4 sources with sentiment breakdown →

Celgene acquired Juno Therapeutics for approximately $9 billion ($87 per share in cash), gaining full ownership of JCAR017 (lisocabtagene maraleucel), a potentially best-in-class CD19-targeted CAR-T cell therapy in pivotal trials for diffuse large B-cell lymphoma.

Key facts

Announced Jan 22, 2018
Closed Mar 06, 2018
Deal value $9.0B
Deal type Acquisition/Merger
Therapeutic area Gene Therapy, Hematology, Oncology
Indications Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma
Key assets JCAR017 (lisocabtagene maraleucel / liso-cel), CAR-T cell therapy platform, CD19-directed cell therapy pipeline
Mechanism CD19-directed CAR-T cell therapy

Related deals — scored

Deal	Year	Value	Outcome
Celgene Corporation / Bristol Myers Squibb (this deal)	2018	$9.0B	68
Celgene Corporation / Bristol Myers Squibb	2015	$2.0B	85
Celgene Corporation / Agios Pharmaceuticals Inc.	2010	$130M	83
Celgene Corporation / Abraxis BioScience Inc.	2010	$2.9B	65
Celgene Corporation / Receptos Inc.	2015	$7.2B	63
Celgene Corporation / Impact Biomedicines	2018	$7.0B	54
Celgene Corporation / Gloucester Pharmaceuticals, Inc.	2009	$640M	40

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2018 deals · Celgene Corporation deals · Gene Therapy deals